Albert David credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
28.528.510.02.15.3
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−229−229−234−283−187
0.07×0.07×0.03×0.01×0.02×
−0.59×−0.59×−0.60×−0.74×−0.60×
5.21×5.21×3.32×0.04×0.12×
−8.57×−41.95×−77.27×−6.04×−4.21×
−1.63×−1.63×−9.61×124.70×78.51×
6.8%6.8%2.5%0.5%1.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ALBERTDAVD₹769.00

Albert David Limited

· Pharma & Health
₹ CrorePeersVALIANTLABHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹439 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt5.32.110.028.528.5
Net Debt-186.7-283.4-233.9-229.3-229.3
Total Debt/Equity0.020.010.030.070.07
Net Debt/Equity-0.60-0.74-0.60-0.59-0.59
Total Debt/EBITDA0.120.043.325.215.21
Net Debt/EBITDA-4.21-6.04-77.27-41.95-8.57
Interest Coverage (EBIT/Interest)78.51124.70-9.61-1.63-1.63
Total Debt/Total Capital %1.680.552.506.786.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.